Endothelial cell senescence and inflammaging: MicroRNAs as biomarkers and innovative therapeutic tools

Francesco Prattichizzo, Massimiliano Bonafè, Artan Ceka, Angelica Giuliani, Maria Rita Rippo, Massimo Re, Roberto Antonicelli, Antonio Domenico Procopio, Fabiola Olivieri

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Aging is accompanied by a progressive decline of endothelial function and a progressive drift toward a systemic pro-inflammatory status that has been designated “inflammaging”. Both phenomena are accelerated and exacerbated in patients with the most common age-related diseases (ARDs), including cancer. The finding that chronic cell stress activates a pro-inflammatory program leading to acquisition of the senescence-associated secretory phenotype (SASP) and to the propagation of senescence to surrounding cells through the secretome, suggests that cell senescence may have a role in both processes. Here we: i) describe the role of cell senescence in endothelial dysfunction, ii) emphasize the contribution of the endothelial cell SASP to inflammaging, and iii) suggest that selective removal of senescent endothelial cells may not only hinder such harmful processes, but also reduce the risk of developing ARDs and their complications. Although in vivo detection and targeting of senescent endothelial cells are still being investigated, it is likely that therapeutic strategies based on antioxidant and anti-inflammatory compounds would involve generalized anti-aging effects also benefiting endothelial cells. MicroRNA (miRNAs) - single-stranded, non-coding RNAs expressed by all living cells and involved in the epigenetic modulation of all transcriptional programs - may constitute an innovative, valuable tool to detect and target senescent endothelial cells and to devise treatments that can slow down the pro-inflammatory program activated in senescent endothelial cells.

Original languageEnglish
Pages (from-to)388-397
Number of pages10
JournalCurrent Drug Targets
Volume17
Issue number4
Publication statusPublished - Mar 1 2016

Fingerprint

Cell Aging
Endothelial cells
Biomarkers
MicroRNAs
Endothelial Cells
Therapeutics
Aging of materials
Phenotype
Untranslated RNA
Epigenomics
Anti-Inflammatory Agents
Antioxidants
Cells
Modulation
Neoplasms

Keywords

  • Cancer
  • Cell senescence
  • Endothelial cells
  • Endothelial dysfunction
  • Inflammaging
  • MicroRNA
  • miR-126-3p
  • NFkB
  • Senescence
  • Senolytic compound
  • T2DM

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Prattichizzo, F., Bonafè, M., Ceka, A., Giuliani, A., Rippo, M. R., Re, M., ... Olivieri, F. (2016). Endothelial cell senescence and inflammaging: MicroRNAs as biomarkers and innovative therapeutic tools. Current Drug Targets, 17(4), 388-397.

Endothelial cell senescence and inflammaging : MicroRNAs as biomarkers and innovative therapeutic tools. / Prattichizzo, Francesco; Bonafè, Massimiliano; Ceka, Artan; Giuliani, Angelica; Rippo, Maria Rita; Re, Massimo; Antonicelli, Roberto; Procopio, Antonio Domenico; Olivieri, Fabiola.

In: Current Drug Targets, Vol. 17, No. 4, 01.03.2016, p. 388-397.

Research output: Contribution to journalArticle

Prattichizzo F, Bonafè M, Ceka A, Giuliani A, Rippo MR, Re M et al. Endothelial cell senescence and inflammaging: MicroRNAs as biomarkers and innovative therapeutic tools. Current Drug Targets. 2016 Mar 1;17(4):388-397.
Prattichizzo, Francesco ; Bonafè, Massimiliano ; Ceka, Artan ; Giuliani, Angelica ; Rippo, Maria Rita ; Re, Massimo ; Antonicelli, Roberto ; Procopio, Antonio Domenico ; Olivieri, Fabiola. / Endothelial cell senescence and inflammaging : MicroRNAs as biomarkers and innovative therapeutic tools. In: Current Drug Targets. 2016 ; Vol. 17, No. 4. pp. 388-397.
@article{8ff0d6b2f4bb47569b181a174e1ad629,
title = "Endothelial cell senescence and inflammaging: MicroRNAs as biomarkers and innovative therapeutic tools",
abstract = "Aging is accompanied by a progressive decline of endothelial function and a progressive drift toward a systemic pro-inflammatory status that has been designated “inflammaging”. Both phenomena are accelerated and exacerbated in patients with the most common age-related diseases (ARDs), including cancer. The finding that chronic cell stress activates a pro-inflammatory program leading to acquisition of the senescence-associated secretory phenotype (SASP) and to the propagation of senescence to surrounding cells through the secretome, suggests that cell senescence may have a role in both processes. Here we: i) describe the role of cell senescence in endothelial dysfunction, ii) emphasize the contribution of the endothelial cell SASP to inflammaging, and iii) suggest that selective removal of senescent endothelial cells may not only hinder such harmful processes, but also reduce the risk of developing ARDs and their complications. Although in vivo detection and targeting of senescent endothelial cells are still being investigated, it is likely that therapeutic strategies based on antioxidant and anti-inflammatory compounds would involve generalized anti-aging effects also benefiting endothelial cells. MicroRNA (miRNAs) - single-stranded, non-coding RNAs expressed by all living cells and involved in the epigenetic modulation of all transcriptional programs - may constitute an innovative, valuable tool to detect and target senescent endothelial cells and to devise treatments that can slow down the pro-inflammatory program activated in senescent endothelial cells.",
keywords = "Cancer, Cell senescence, Endothelial cells, Endothelial dysfunction, Inflammaging, MicroRNA, miR-126-3p, NFkB, Senescence, Senolytic compound, T2DM",
author = "Francesco Prattichizzo and Massimiliano Bonaf{\`e} and Artan Ceka and Angelica Giuliani and Rippo, {Maria Rita} and Massimo Re and Roberto Antonicelli and Procopio, {Antonio Domenico} and Fabiola Olivieri",
year = "2016",
month = "3",
day = "1",
language = "English",
volume = "17",
pages = "388--397",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Endothelial cell senescence and inflammaging

T2 - MicroRNAs as biomarkers and innovative therapeutic tools

AU - Prattichizzo, Francesco

AU - Bonafè, Massimiliano

AU - Ceka, Artan

AU - Giuliani, Angelica

AU - Rippo, Maria Rita

AU - Re, Massimo

AU - Antonicelli, Roberto

AU - Procopio, Antonio Domenico

AU - Olivieri, Fabiola

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Aging is accompanied by a progressive decline of endothelial function and a progressive drift toward a systemic pro-inflammatory status that has been designated “inflammaging”. Both phenomena are accelerated and exacerbated in patients with the most common age-related diseases (ARDs), including cancer. The finding that chronic cell stress activates a pro-inflammatory program leading to acquisition of the senescence-associated secretory phenotype (SASP) and to the propagation of senescence to surrounding cells through the secretome, suggests that cell senescence may have a role in both processes. Here we: i) describe the role of cell senescence in endothelial dysfunction, ii) emphasize the contribution of the endothelial cell SASP to inflammaging, and iii) suggest that selective removal of senescent endothelial cells may not only hinder such harmful processes, but also reduce the risk of developing ARDs and their complications. Although in vivo detection and targeting of senescent endothelial cells are still being investigated, it is likely that therapeutic strategies based on antioxidant and anti-inflammatory compounds would involve generalized anti-aging effects also benefiting endothelial cells. MicroRNA (miRNAs) - single-stranded, non-coding RNAs expressed by all living cells and involved in the epigenetic modulation of all transcriptional programs - may constitute an innovative, valuable tool to detect and target senescent endothelial cells and to devise treatments that can slow down the pro-inflammatory program activated in senescent endothelial cells.

AB - Aging is accompanied by a progressive decline of endothelial function and a progressive drift toward a systemic pro-inflammatory status that has been designated “inflammaging”. Both phenomena are accelerated and exacerbated in patients with the most common age-related diseases (ARDs), including cancer. The finding that chronic cell stress activates a pro-inflammatory program leading to acquisition of the senescence-associated secretory phenotype (SASP) and to the propagation of senescence to surrounding cells through the secretome, suggests that cell senescence may have a role in both processes. Here we: i) describe the role of cell senescence in endothelial dysfunction, ii) emphasize the contribution of the endothelial cell SASP to inflammaging, and iii) suggest that selective removal of senescent endothelial cells may not only hinder such harmful processes, but also reduce the risk of developing ARDs and their complications. Although in vivo detection and targeting of senescent endothelial cells are still being investigated, it is likely that therapeutic strategies based on antioxidant and anti-inflammatory compounds would involve generalized anti-aging effects also benefiting endothelial cells. MicroRNA (miRNAs) - single-stranded, non-coding RNAs expressed by all living cells and involved in the epigenetic modulation of all transcriptional programs - may constitute an innovative, valuable tool to detect and target senescent endothelial cells and to devise treatments that can slow down the pro-inflammatory program activated in senescent endothelial cells.

KW - Cancer

KW - Cell senescence

KW - Endothelial cells

KW - Endothelial dysfunction

KW - Inflammaging

KW - MicroRNA

KW - miR-126-3p

KW - NFkB

KW - Senescence

KW - Senolytic compound

KW - T2DM

UR - http://www.scopus.com/inward/record.url?scp=84960111815&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960111815&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84960111815

VL - 17

SP - 388

EP - 397

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 4

ER -